Associate Scientist
Cartography Biosciences
Associate Scientist
Cartography Biosciences
Develops precision immunotherapies targeting antigens
About Cartography Biosciences
Cartography Biosciences is advancing a differentiated oncology pipeline of antibody-based therapies designed to target tumors with unprecedented precision. The company’s ATLAS and SUMMIT discovery platforms are powered by an industry-leading, fully integrated dataset spanning hundreds of thousands of cell states across healthy tissues alongside large-scale single-cell profiling of patient tumors. By combining petabyte-scale proprietary data, machine learning, and AI-driven biological insights, Cartography is identifying highly specific tumor targets and logic-gated target combinations to generate therapies engineered for maximal tumor selectivity and meaningful patient impact. The company’s lead program, CBI-1214, is a T-cell engager in development for colorectal cancer. CBI-1214 entered the clinic in early 2026 and is currently enrolling and treating patients in a phase 1 trial.
Cartography Biosciences is seeking a highly motivated Associate Scientist to join our Pharmacology team and play a pivotal role in the in vitro development and characterization of novel T cell engagers across our pipeline. This lab-focused role centers on high-throughput functional screening as well as secondary characterization assays. The ideal candidate brings experience in T cell biology, in vitro assay development and MoA studies.
Key Responsibilities:
Qualifications:
Preferred:
Location
South San Francisco, CA — on-site, 5 days a week (Pharmacology team).
[{'location': 'SSF-2', 'currency': 'USD', 'frequency': 'YEAR', 'rangeStart': 115000.0, 'rangeEnd': 125000.0, 'isRemote': False}]
Develops precision immunotherapies targeting antigens
Cartography Biosciences develops precision cancer immunotherapies. It identifies therapeutic targets by analyzing cancers through antigen expression instead of histology or genetic mutations, enabling therapies that specifically engage tumor cells while aiming to minimize harm to healthy tissue. The company designs and commercializes targeted immunotherapies and seeks druggable targets in cancers that are currently untreatable, striving for treatments that are as safe as they are effective and broadly applicable across tumor cells within a patient. In short, its goal is to deliver precise, safe, and potent cancer treatments by pairing a unique target-identification approach with immunotherapy platforms, and to bring these therapies to healthcare providers and patients through commercialization.
Explore more opportunities at Cartography Biosciences